Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $721K | $1.37M | $146K | $0.00 | $0.00 | $112K | $609K | $1.37M | $3.31M |
| Revenue growth | — | — | 90.1% | -89.3% | -100.0% | — | — | 442.1% | 124.3% | 142.7% |
| Gross profit | — | -$370K | $1.21M | $31.6K | $0.00 | $0.00 | $93.0K | $482K | $1.06M | $2.22M |
| Gross margin | — | -51.3% | 88.1% | 21.6% | — | — | 82.9% | 79.3% | 77.8% | 66.9% |
| Operating income | — | -$15.5M | -$1.50M | -$969K | -$378K | -$90.7K | -$3.32M | -$3.17M | -$2.46M | -$2.52M |
| Operating margin | — | -2154.4% | -109.8% | -663.0% | — | — | -2958.2% | -520.6% | -180.0% | -76.0% |
| Net income | — | -$15.0M | -$1.54M | -$1.19M | -$90.9K | -$90.7K | -$3.17M | -$3.17M | -$2.32M | -$2.51M |
| Net margin | — | -2077.4% | -112.5% | -817.4% | — | — | -2825.6% | -521.2% | -170.2% | -75.8% |
| EPS (diluted) | — | -$1.02 | -$0.07 | -$0.05 | $0.27 | -$0.03 | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -$4.90M | -$874K | -$922K | -$53.8K | -$120K | -$3.71M | -$3.17M | -$2.23M | -$865K |
| Capital expenditures | — | — | — | $0.00 | $0.00 | $0.00 | $60.0K | $7.24K | $155K | $275K |
| Free cash flow | — | — | — | -$922K | -$53.8K | -$120K | -$3.77M | -$3.18M | -$2.39M | -$1.14M |
| Share buybacks | — | $471.00 | — | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $10.4M | $694K | $637K | $20.3K | $161K | $1.41M | $2.05M | $929K | $284K | $549K |
| Total assets | $14.1M | $1.42M | $975K | $277K | $12.1K | $1.47M | $3.05M | $1.88M | $1.19M | $1.85M |
| Total liabilities | $1.57M | $941K | $1.06M | $1.49M | $1.01M | $673K | $856K | $839K | $676K | $2.80M |
| Long-term debt | — | — | — | — | — | $0.00 | — | — | — | — |
| Shareholders' equity | $12.5M | $483K | -$82.0K | -$1.21M | -$504K | $793K | $2.19M | $1.04M | $514K | -$957K |
| Retained earnings | -$5.70M | -$20.7M | -$22.2M | -$23.4M | -$23.2M | -$23.6M | -$26.8M | -$29.9M | -$32.3M | -$34.8M |
| Shares (wtd avg diluted) | 9.93M | 14.6M | 23.3M | 23.7M | 25.7M | 30.3M | 40.0M | 42.1M | 45.4M | 47.3M |
Every figure is extracted from Nuo Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.